by Plus Therapeutics | Sep 17, 2025 | GBM, PBC
Each September, Childhood Cancer Awareness Month (#CCAM) serves as a powerful reminder to honor children and families affected by pediatric cancer and to raise awareness for the urgent need for new treatment options. At Plus Therapeutics (Nasdaq: PSTV), we are deeply...
by Plus Therapeutics | Jun 25, 2025 | PBC
We are proud to announce that the U.S. Food and Drug Administration (FDA) has officially cleared Plus Therapeutics’ Investigational New Drug (IND) application for REYOBIQ™, a novel radiotherapeutic under development for the treatment of pediatric patients with...
by Plus Therapeutics | Jun 25, 2025 | PBC
FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial Plus Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has officially cleared its Investigational New Drug (IND) application for REYOBIQ™, a...
by Plus Therapeutics | May 1, 2025 | GBM, LM, PBC, Uncategorized
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
by Plus Therapeutics | Apr 12, 2025 | GBM, LM, PBC, Uncategorized
Advancing Radiotherapeutic Solutions for Rare Cancers At Plus Therapeutics, our mission is clear: to develop safe, effective, and lasting solutions for patients facing rare and hard-to-treat cancers. Every day, our dedicated team works alongside clinicians and...
by Plus Therapeutics | Apr 8, 2025 | GBM, LM, PBC, Uncategorized
The Power of Radionuclide-Based Therapies in Modern Cancer Treatment Radionuclide-based therapies represent a rapidly evolving frontier in precision oncology, offering targeted treatment options for a wide range of cancer types. These therapies utilize radionuclides...
Recent Comments